Sareum Holdings plc (SAR) ORD GBP0.0125
1.50p
(5.36%)
- Add to watchlist
- Create an alert
- This stock can be held in a
1.50p
(5.36%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
1.50p
(5.36%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
28.00p
27.83p
82.50p
£28.61 million
28.00p
25.55p
10.25p
n/a
0.50p (1.75%) Previous:
0.50p
122,900
n/a
3,000
Performance
Not available for this stock.
Fundamental data
| Year ending: | 30/06/2023 | 30/06/2022 |
|---|---|---|
| Revenue (£m) | n/a | n/a |
| Profit before tax (£m) | (4.03) | 2.58 |
| Adjusted EPS (p): | (4.70) | (3.20) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Sareum announces positive results from kinase inhibitor trial
1 July 2024 11:23
-
Sareum allowed European patent for primary kinase inhibitor asset
15 March 2024 13:11
-
Sareum reports positive progress in psoriasis programme
15 February 2024 13:22
-
US patent allowance
2 September 2024 07:00
-
Management Changes
10 July 2024 07:00
-
Positive Data from SDC-1801 Phase 1 Clinical Trial
1 July 2024 07:00
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.